Follow us on LinkedIn - https://www.linkedin.com/company/fatty-liver-alliance/
Metabolic dysfunction-Associated Steatotic Liver Disease
Fatty Liver Disease (MASLD/MASH)
Follow us on LinkedIn - https://www.linkedin.com/company/fatty-liver-alliance/
Signed in as:
filler@godaddy.com
Fatty Liver Disease (MASLD/MASH)
Inspired and influenced greatly by this week's United Nations General Assembly Side-Event in NYC, we created this blog that we hope will contribute to the global discussion and work already being done by experts like Jeffrey V. Lazarus from Barcelona Institute for Global health (ISGlobal) the CUNY Graduate School of Public Health Policy, and Economist Impact who hosted this valuable global representation of health experts.
Madeleine Chang is a high school senior at Arnold O. Beckman High School in Orange County, California,. She has a strong interest in biology and medicine, and has (with her brother Devon Chang, also a high-school student) been working with Dr. Mazen Noureddin, MD, MHSc, Hepatologist from Houston Research Institute on MASLD research for the last two to three years. We used the words 'heart warming' because it is so great seeing people as young as high-school students passionately exploring science in an effort to help patients! Madeleine is the first author of this paper!
Initiating and Monitoring Resmetirom in Patients with MASH/NASH and Moderate to noncirrhotic Advanced Fibrosis
Let's take a moment and revisit this very recent paper by Mazen Noureddin, Michael R. Charlton, Stephen A. Harrison, Meena B. Bansal, Naim Alkhouri, Rohit Loomba, Arun J. Sanyal, Mary E. Rinella
Effective communication between patients and physicians is fundamental to delivering high-quality healthcare. However, several inherent challenges can make these interactions less than optimal. Patients often enter the consultation room with a sense of apprehension, particularly when dealing with chronic conditions such as fatty liver disease, obesity, or type-2 diabetes. They may respect their doctors greatly but feel inhibited, nervous, and unsure about how to convey their concerns effectively.
Millions are affected by fatty liver disease, and raising awareness is crucial. Wendy Schaufert has dedicated 10 years to working with patients, focusing on metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), formerly NAFLD/NASH.
Dr. Mark Swain, Hepatologist answers an audience question at our Calgary event and shares one real world patient story about Ozempic and the impact it had on their life and daily routine.
Dr. Swain provides an in-depth explanation of Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic dysfunction-Associated Steatohepatitis (MASH), highlighting the importance of recognizing and addressing these conditions early.
Video #2: Check out the interest from the Calgary, AB community.
Liam Swain sharing the Madrigal Pharmaceuticals liver model on Global Fatty Liver Day.
We had an incredible event on June 13, 2024, for Global Fatty Liver Day! It was a privilege to host such a knowledgeable and engaged community in Calgary. As the President and Founder of the Fatty Liver Alliance, I’m thrilled to share some highlights and key takeaways from our first presentation titled "Your Liver, Your Health: Understanding Metabolic Dysfunction."
Fatty liver disease, encompassing both Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic dysfunction-Associated Steatohepatitis (MASH), is a growing concern globally. By the time symptoms appear, significant liver damage might have already occurred. Early assessment can prevent progression, manage comorbidities and ensure that patients receive tailored treatment.
Dr. Jason Fung explains that intermittent fasting is an effective strategy for managing and reversing fatty liver disease, including Metabolic Associated Steatotic Liver Disease (MASLD) and Metabolic Associated Steatohepatitis (MASH).
Just posted here is the complete set of videos from our Primary Care Summit. With 4.5 hours of presentations approved for CME credits in its live version, feel confident that the information shared is accurate and reputable.
Presentations were done by internationally recognized and respected liver and metabolic health experts.
The Fatty Liver Alliance a Canada-based advocacy group, is calling for supporters to sign a petition asking Madrigal Pharmaceuticals to apply to Canadian regulators for approval of Rezdiffra (resmetirom), the company’s oral therapy for metabolic dysfunction-associated steatohepatitis (MASH).
https://liverdiseasenews.com/news/nonprofits-petition-aims-expedite-canadian-access-rezdiffra/
Today, we're taking a crucial step forward in advocating for Canadians diagnosed with MASH (Metabolic dysfunction-Associated Steatohepatitis).
We've launched a petition asking Madrigal Pharmaceuticals to apply to Health Canada, so that Canadians can have access to Rezdiffra—a vital treatment for MASH.
Your support is essential! Please take a moment to sign our petition and share this with your network. Together, we can make a difference!
🔗 Sign the Petition Here: https://globalliver.salsalabs.org/petitionrezdiffracanada
🔗 Read Our Media Release: Urgent Call to Action: Canadians Deserve Equal Access to Life-Saving Liver Treatment--Sign the Petition Now!
Thank you for standing with us in this important cause.
Our amazing team of full and part-time volunteers are committed to helping others. We take our convictions and turn them into action. Think you would be a good fit? Get in touch for more information!
Our nonprofit charity was created to build a supportive community. Canada’s population is about 38.8M with an estimated 11.64M who may have Metabolic Dysfunction Associated Liver Disease (MASLD) (formerly NAFLD). Of those, an estimated 20% - 25% will progress to cirrhosis and suffer with Metabolic-dysfunction Associated Steatohepatitis (MASH) (formerly NASH).
We raise awareness about the risks, causes and complications of fatty liver disease and help those already diagnosed with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) by advocating for access to approved treatments and care.
Your support and contributions will enable our Registered Charity to meet our goals and your generous donations will fund our mission and purpose. Charity #79690 4704 RR0001
We will issue a tax receipt for donations of $18.00 or greater.
**Best option for us, is e-transfer to donations@fattyliver.ca
In the comment section, we need your full name and address so we can issue a tax receipt. Other payment options below.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.